- JP-listed companies
- Immuno-Biological Laboratories Co., Ltd.
- Income statement
Immuno-Biological Laboratories Co., Ltd. (4570) Income statement
Market cap
¥8.9B
P/E ratio
25.7x
Develops antibody-based diagnostic tools and testing services for medical research, plus manufactures cosmetics using human-type collagen from silkworms.
| 2012/03 | 2013/03 | 2014/03 | 2015/03 | 2016/03 | 2017/03 | 2018/03 | 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | 2026/03 | |
| Revenue | 915 | 800 | 670 | 729 | 718 | 742 | 758 | 781 | 577 | 603 | 648 | 795 | 817 | 970 | 1,005 |
| Revenue growth (%) | - | ||||||||||||||
| Cost of revenue | - | - | - | 362 | 266 | 327 | 281 | 321 | 359 | 256 | 271 | 268 | 299 | 335 | 298 |
| Gross profit | - | - | - | 367 | 452 | 415 | 477 | 460 | 217 | 347 | 377 | 527 | 517 | 634 | 707 |
| Gross margin (%) | - | - | - | ||||||||||||
| Operating margin (%) | - | - | - | ||||||||||||
| Operating expenses | - | - | - | 549 | 527 | 1,572 | 526 | 634 | 813 | 588 | 499 | 468 | 413 | 425 | 426 |
| Operating income | - | - | - | -182 | -75 | -1,157 | -49 | -174 | -595 | -241 | -122 | 58 | 104 | 209 | 281 |
| Income before tax | 55 | 80 | -100 | -139 | -82 | -1,170 | -49 | -156 | -679 | -311 | -243 | -150 | 125 | 210 | 301 |
| Pretax margin (%) | 6 | 10.1 | -14.9 | -19.1 | -11.4 | -157.8 | -6.5 | -19.9 | -117.7 | -51.5 | -37.6 | -18.8 | 15.4 | 21.6 | 29.9 |
| Provision for income taxes | - | - | - | 5 | 2 | 6 | 1 | 3 | 9 | 8 | 9 | 9 | -62 | -39 | -28 |
| Effective tax rate (%) | - | - | - | ||||||||||||
| Net income | 43 | 153 | -127 | -158 | -32 | -2,094 | -53 | -167 | -668 | -319 | -259 | -290 | 187 | 249 | 329 |
| Earnings per share | 6.94 | 24.83 | -17.99 | -24.2 | -4.86 | -287.52 | -7.01 | -19.82 | -76 | -34.23 | -27.78 | -31.1 | 20.05 | 26.74 | 35.33 |
| Dividend per share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6 |